# References

## Core Drug Repurposing Literature

1. **Pushpakom S, Iorio F, Eyers PA, et al.** Drug repurposing: progress, challenges and recommendations. *Nat Rev Drug Discov.* 2019;18(1):41–58. PMID: 30310233

2. **Brown AS, Patel CJ.** A standard database for drug repositioning. *Sci Data.* 2017;4:170029. PMID: 28291243

3. **Ashburn TT, Thor KB.** Drug repositioning: identifying and developing new uses for existing drugs. *Nat Rev Drug Discov.* 2004;3(8):673–683. PMID: 15286734

---

## Data Sources & Databases

4. **Ochoa D, Hercules A, Carmona M, et al.** Open Targets Platform: supporting systematic drug–target identification and prioritisation. *Nucleic Acids Res.* 2021;49(D1):D1302–D1310. PMID: 33060197  
   URL: https://platform.opentargets.org

5. **Gaulton A, Hersey A, Nowotka M, et al.** The ChEMBL database in 2017. *Nucleic Acids Res.* 2017;45(D1):D945–D954. PMID: 27899562  
   URL: https://www.ebi.ac.uk/chembl

6. **Freshour SL, Kiwala S, Cotto KC, et al.** Integration of the Drug–Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. *Nucleic Acids Res.* 2021;49(D1):D1144–D1151. PMID: 33237278  
   URL: https://www.dgidb.org

7. **Sayers EW, Bolton EE, Brister JR, et al.** Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.* 2022;50(D1):D20–D26. PMID: 34850941  
   PubMed E-utilities: https://eutils.ncbi.nlm.nih.gov

8. **ClinicalTrials.gov.** U.S. National Library of Medicine.  
   URL: https://clinicaltrials.gov

---

## Validation Drug-Disease Cases

### Mechanism-Congruent Cases

9. **Galiè N, Ghofrani HA, Torbicki A, et al.** Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med.* 2005;353(20):2148–2157. PMID: 16291984  
   *(Sildenafil → pulmonary arterial hypertension)*

10. **Cohen SB, Emery P, Greenwald MW, et al.** Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. *Arthritis Rheum.* 2006;54(9):2793–2806. PMID: 16951627  
    *(Rituximab → rheumatoid arthritis)*

11. **Lord JM, Flight IH, Norman RJ.** Metformin in polycystic ovary syndrome: systematic review and meta-analysis. *BMJ.* 2003;327(7421):951–953. PMID: 14576245  
    *(Metformin → polycystic ovary syndrome)*

12. **Ghofrani HA, Seeger W, Grimminger F.** Imatinib for the treatment of pulmonary arterial hypertension. *N Engl J Med.* 2005;353(13):1412–1413. PMID: 16192490  
    *(Imatinib → pulmonary arterial hypertension)*

### Empirical Cases

13. **Elwood PC.** Aspirin: past, present, and future. *Clin Med (Lond).* 2001;1(2):132–137. PMID: 11446622  
    *(Aspirin → coronary artery disease)*

14. **Koller WC, Royse VL.** Efficacy of propranolol in essential tremor. *Neurology.* 1986;36(4):456–460. PMID: 3960325  
    *(Propranolol → essential tremor)*

15. **Messenger AG, Rundegren J.** Minoxidil: mechanisms of action on hair growth. *Br J Dermatol.* 2004;150(2):186–194. PMID: 14996087  
    *(Minoxidil → alopecia)*

### Tuning Set Cases

16. **Singhal S, Mehta J, Desikan R, et al.** Antitumor activity of thalidomide in refractory multiple myeloma. *N Engl J Med.* 1999;341(21):1565–1571. PMID: 10564685  
    *(Thalidomide → multiple myeloma)*

17. **Schwab RS, England AC, Poskanzer DC, Young RR.** Amantadine in the treatment of Parkinson's disease. *JAMA.* 1969;208(7):1168–1170. PMID: 4142340  
    *(Amantadine → Parkinson disease)*

18. **Vogel VG, Costantino JP, Wickerham DL, et al.** Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. *JAMA.* 2006;295(23):2727–2741. PMID: 16754728  
    *(Raloxifene → breast carcinoma)*

19. **Kaufman KD, Olsen EA, Whiting D, et al.** Finasteride in the treatment of men with androgenetic alopecia. *J Am Acad Dermatol.* 1998;39(4):578–589. PMID: 9777765  
    *(Finasteride → alopecia)*

---

## Mechanistic Target References

20. **Corbin JD, Francis SH.** Cyclic GMP phosphodiesterase-5: target of sildenafil. *J Biol Chem.* 1999;274(20):13729–13732. PMID: 10318771  
    *(PDE5A as sildenafil target)*

21. **Druker BJ, Talpaz M, Resta DJ, et al.** Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med.* 2001;344(14):1031–1037. PMID: 11287975  
    *(Imatinib → ABL1/PDGFR targets)*

22. **Zhou G, Myers R, Li Y, et al.** Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest.* 2001;108(8):1167–1174. PMID: 11602624  
    *(Metformin → AMPK/PRKAA1/PRKAA2)*

23. **Maloney DG, Grillo-López AJ, White CA, et al.** IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. *Blood.* 1997;90(6):2188–2195. PMID: 9310469  
    *(Rituximab → MS4A1/CD20)*

---

## Graph-Based & Computational Methods

24. **Barabási AL, Gulbahce N, Loscalzo J.** Network medicine: a network-based approach to human disease. *Nat Rev Genet.* 2011;12(1):56–68. PMID: 21164525

25. **Himmelstein DS, Lizee A, Hessler C, et al.** Systematic integration of biomedical knowledge prioritizes drugs for repurposing. *eLife.* 2017;6:e26726. PMID: 28936969

26. **Lotfi Shahreza M, Ghadiri N, Mousavi SR, et al.** A review of network-based approaches to drug repositioning. *Brief Bioinform.* 2018;19(5):878–892. PMID: 28334136

---

## Software & Tools

27. **Hagberg AA, Schult DA, Swart PJ.** Exploring network structure, dynamics, and function using NetworkX. In: *Proceedings of the 7th Python in Science Conference.* 2008:11–15.

28. **Aiohttp Contributors.** aiohttp: Asynchronous HTTP client/server for Python. Version 3.x. https://docs.aiohttp.org